Skip to main content
. 2019 Jan 23;2019:9357203. doi: 10.1155/2019/9357203

Table 1.

Baseline clinical characteristics between patients with CIN and those without CIN.

Variables CIN(n=29) Non-CIN(n=211) P value

Male,n (%) 18 (62.1) 161 (76.3) 0.099
Age (years) 71.07±13.77 63.06±12.7 0.002
Smoking,n (%) 14 (48.3) 118 (55.9) 0.438
Hypertention,n (%) 24 (82.8) 126 (59.7) 0.016
Diabetes mellitus,n (%) 13 (44.8) 50 (23.7) 0.015
Systolic BP (mm Hg) 127.21±22.72 128.39±22.02 0.585
Diastolic BP (mm Hg) 74.59±13.2 76.65±14.3 0.519
Heart rate (t/min) 82.59±15.99 80.33±17.4 0.486
LV (cm) 5.04±0.49 4.83±0.6 0.029
LVEF (%) 0.47±0.12 0.53±0.11 0.02
Contrast dose (mL) 109.66±23.22 105.17±15.72 0.152
Hydration,n (%) 16 (55.2) 52 (24.6) 0.001
Number of diseased vessels, n 3.1±1.59 2.78±1.26 0.336
Medication,n (%)
Aspirin 27 (93.1) 203 (96.2) 0.433
Ticagrelor 29 (1) 210 (99.5) 0.71
β-Blocker 24 (82.8) 175 (82.9) 0.981
ACEI/ARB 11 (37.9) 134 (63.5) 0.008
CCB 4 (13.8) 16(7.6) 0.257
Statin 28 (96.6) 203 (96.2) 0.927
Diuretics 16 (55.2) 65 (30.8) 0.009
Hospitalization (days) 13.62±9.04 10.02±10.17 0.009
Hospitalization costs (RMB) 65245.52±30207.06 59278.88±45699.02 0.127

Data were presented as means ± standard deviation or number(%). BP, blood pressure; LV, left ventricular; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.